ライフサイエンス出版株式会社

FacebookTwitterInstagram
menu

Japanese Pharmacology & Therapeutics(JPT)

Vol. 35 Suppl. 1 2007

■ Clinical studies of Mitiglinide, a Rapid and Short Acting Insulin Secretagogue

Evaluation of Glucose Lowering Effects of Mitiglinide in Type 2 Diabetes Patients
―Placebo-controlled, Parallel Group Comparative Dose-response Study―

T. Tanaka, et al.

Jpn Pharmacol Ther 2007 35(s1) s5-21


Long-term Study of a Rapid and Short Acting Insulin Secretagogue Mitiglinide in Type 2 Diabetes Patients

T. Tanaka, et al.

Jpn Pharmacol Ther 2007 35(s1) s23-37


Clinical Pharmacological Study of Mitiglinide in Type 2 Diabetes Patients with Voglibose Monotherapy

Y. Tohi, et al.

Jpn Pharmacol Ther 2007 35(s1) s39-49


Concomitant Effects of a Rapid and Short Acting Insulin Secretagogue Mitiglinide in Type 2 Diabetes Patients with Inadequate Control of Blood Glucose with Voglibose Monotherapy
―Phase II / III Double Blind Comparative Study―

K. Kaku, et al.

Jpn Pharmacol Ther 2007 35(s1) s51-72


Long-term Concomitant Administration Study of a Rapid and Short Acting Insulin Secretagogue Mitiglinide in Combination with an α-Glucosidase Inhibitor Voglibose in Type 2 Diabetes Patients
―Extension Study of Phase II / III Double Blind Comparative Study―

K. Kaku, et al.

Jpn Pharmacol Ther 2007 35(s1) s73-91


Concomitant Effects of a Rapid and Short Acting Insulin Secretagogue Mitiglinide in Type 2 Diabetes Patients with Inadequate Control with α-Glucosidase Inhibitor Monotherapy
―Phase III Open Label Study―

T. Osonoii, et al.

Jpn Pharmacol Ther 2007 35(s1) s93-104